Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Articles, guides, and regulatory updates from our community.
New research across 85 trials finds incretin-based therapies modestly reduce blood pressure and lower mortality in adults with obesity. Read the evidence.
By Peptide Association Research Team
The GLP-1 revolution has rewritten the rules of obesity treatment. How incretin-based peptide therapies achieve what diet and exercise alone cannot, and what comes next.
By Peptide Association Editorial Team